Precision BioSciences Expands ELIMINATE-B Trial in EU
Durham, North Carolina, U.S. | April 15, 2026 Precision BioSciences has announced a significant clinical and regulatory milestone with...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Durham, North Carolina, U.S. | April 15, 2026 Precision BioSciences has announced a significant clinical and regulatory milestone with...
December 21, 2025 | Beijing, China — T-MAXIMUM Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has...
Basel, Switzerland, December 2, 2025 —Roche has announced the launch of a rapid 15-minute point-of-care PCR test capable of...
Tarrytown, New York & Somerville, Massachusetts, December 1, 2025 — Regeneron and Tessera Therapeutics have announced a global collaboration...
Dateline Introduction Shanghai, China & Cambridge, Massachusetts — November 17, 2025 — YolTech Therapeutics has received FDA Investigational New...
ROCKVILLE, Md., Oct. 6, 2025 — MaxCyte, Inc. announced a Strategic Platform License (SPL) agreement with Moonlight Bio to...
CAMBRIDGE, Mass., Sept. 25, 2025 — Intellia Therapeutics announced positive longer-term Phase 1 data for its investigational CRISPR-based therapy...
